NCT00766350已完成4 期
A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Mean change from baseline to endpoint in the total score of Fibromyalgia Impact Questionnaire
研究概览
简要总结
Quetiapine, a second generation antipsychotic, has shown beneficial activity on fibromyalgia symptomatology, administered as add-on treatment, in a sample of 35 patients. The purpose of the present study is to compare, in a controlled setting, the efficacy and the tolerability of quetiapine extended release with amitriptyline in the treatment of patients with fibromyalgia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 18 70 years.
- •Meeting American College of Rheumatology criteria for primary fibromyalgia: widespread aching pain in all four quadrants of the body and axial skeleton and greater than or equal to 11 of 18 tender points under digital palpation examination.
- •A FIQ total score (0 100) of 40 or greater
- •A score of 4 or greater on the average pain item of the BPI
- •Written informed consent
- •Female patients of childbearing potential must be using a reliable contraceptive method and have a negative urine human chorionic gonadotropin (HCG) test at enrolment.
- •Able to understand and comply with the requirements of the study.
排除标准
- •Evidence of current traumatic injury, inflammatory rheumatic disease, or infectious or endocrine related joint disease.
- •A lifetime history of hypomania, mania, psychosis or dementia.
- •Current primary Axis I diagnosis other than major depressive disorder
- •Substance or alcohol dependence at enrolment and within the past 12 months (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM IV
- •Severe depression as evidenced by a Beck Depression Inventory score ≥ 30
- •Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
- •History of seizures
- •Known lack of response to 2, or more than 2, different type of antidepressants in depression of fibromyalgia.
- •Pregnancy or breast feeding.
- •Patients with a history of urinary retention, angle closure glaucoma, or increased intraocular pressure.
- •Patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions which would predispose patients to severe hypotension (dehydration, hypovolemia and treatment with antihypertensive medications).
- •Patients who have received IMAOs, SSRIs or other antidepressants within two weeks of randomization.
- •Current or past history of kidney or liver insufficiency
- •Prior to randomization. Unwillingness to discontinue previously prescribed drugs for fibromyalgia other than those authorized in the protocol, as acetaminophen and bromazepam
- •Patients who have received quetiapine or amitriptyline within 1 year of randomization.
- •Patients with known intolerance or lack of response to quetiapine fumarate and/or amitriptyline, as judged by the investigator
- •Use of any of the following cytochrome P450 3A4 inhibitors within 14 days of enrolment, including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, and saquinavir
- •Use of any of the following cytochrome P450 inducers within 14 days of enrolment, including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's wort, and glucocorticoids
- •Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM IV criteria within 4 weeks of enrolment
- •Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment, with clinical relevance.
- •Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension), as judged by the investigator
- •Involvement in planning and conduct of the study
- •Previous enrolments or randomisation of treatment in the present study.
- •Participation in another trial with drugs within 4 weeks of enrolment into this study or a longer period in accordance with local requirements.
- •Patients with uncontrolled Diabetes Mellitus (DM)
- •An absolute neutrophil count (ANC) equal or lower than 1.5 x 109 per liter.
- •Patients who show at the randomization visit a reduction in the FIQ total score equal or greater than 20% from the screening visit.
研究组 & 干预措施
amitriptyline
Active Comparator
干预措施: amitriptyline (Drug)
quetiapine
Experimental
干预措施: quetiapine (Drug)
结局指标
主要结局
Mean change from baseline to endpoint in the total score of Fibromyalgia Impact Questionnaire
时间窗: baseline, 4, 8, 12 and 16 weeks
次要结局
- Discontinuation rates due to treatment-related adverse events, proportion of patients experiencing adverse events, proportion of patients experiencing serious adverse events, adverse events description and classification.(baseline, 0, 4, 8, 12 and 16 weeks)
- Change from baseline to endpoint in the scores of the Brief Pain Inventory, the Pittsburgh Sleep Quality Inventory, the Beck Depression Inventory, and the State and Trait Anxiety Inventory(baseline, 4, 8, 12 and 16 weeks)
研究者
Elena Pita Calandre
Professor of Pharmacology
Universidad de Granada
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot StudyFibromyalgiaNCT00983320Université de Sherbrooke52
已完成
2 期
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With FibromyalgiaFibromyalgiaNCT05128162Kevin Boehnke17
终止
2 期
A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site StudyAnorexia NervosaNCT00584688University of South Florida24
Unknown
4 期
Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With SchizophreniaAcute SchizophreniaNCT00838032Sichuan University70
已完成
不适用
Trial of Quetiapine in Anorexia NervosaAnorexia NervosaNCT00518973University of California, San Diego21